Unpacking the Role of Cannabis in Oncology as Reclassification of the Drug Pends
Brooke Worster, MD, MS, FACP, and chief medical officer at EO Care, details what oncologists should know about medical cannabis pending the expectant marijuana reclassification from a Schedule I to a Schedule III drug.
United States Dronabinol Marinol Brooke Worster Business Master Program Senate Majority Leader Chuck Schumer Jefferson Health
Source: onclive.com